276 related articles for article (PubMed ID: 36678521)
1. Therapeutic Strategies to Activate p53.
Aguilar A; Wang S
Pharmaceuticals (Basel); 2022 Dec; 16(1):. PubMed ID: 36678521
[TBL] [Abstract][Full Text] [Related]
2. Ensemble-based virtual screening reveals dual-inhibitors for the p53-MDM2/MDMX interactions.
Barakat K; Mane J; Friesen D; Tuszynski J
J Mol Graph Model; 2010 Feb; 28(6):555-68. PubMed ID: 20056466
[TBL] [Abstract][Full Text] [Related]
3. Chemical Variations on the p53 Reactivation Theme.
Ribeiro CJ; Rodrigues CM; Moreira R; Santos MM
Pharmaceuticals (Basel); 2016 May; 9(2):. PubMed ID: 27187415
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic opportunities in cancer therapy: targeting the p53-MDM2/MDMX interactions.
Munisamy M; Mukherjee N; Thomas L; Pham AT; Shakeri A; Zhao Y; Kolesar J; Rao PPN; Rangnekar VM; Rao M
Am J Cancer Res; 2021; 11(12):5762-5781. PubMed ID: 35018225
[TBL] [Abstract][Full Text] [Related]
5. An Update on MDMX and Dual MDM2/X Inhibitors.
Espadinha M; Barcherini V; Lopes EA; Santos MMM
Curr Top Med Chem; 2018; 18(8):647-660. PubMed ID: 29866007
[TBL] [Abstract][Full Text] [Related]
6. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
[TBL] [Abstract][Full Text] [Related]
7. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
Hu B; Gilkes DM; Chen J
Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
[TBL] [Abstract][Full Text] [Related]
8. 1,4,5-Trisubstituted Imidazole-Based p53-MDM2/MDMX Antagonists with Aliphatic Linkers for Conjugation with Biological Carriers.
Twarda-Clapa A; Krzanik S; Kubica K; Guzik K; Labuzek B; Neochoritis CG; Khoury K; Kowalska K; Czub M; Dubin G; Dömling A; Skalniak L; Holak TA
J Med Chem; 2017 May; 60(10):4234-4244. PubMed ID: 28482147
[TBL] [Abstract][Full Text] [Related]
9. Controlling the Mdm2-Mdmx-p53 Circuit.
Waning DL; Lehman JA; Batuello CN; Mayo LD
Pharmaceuticals (Basel); 2010 May; 3(5):1576-1593. PubMed ID: 20651945
[TBL] [Abstract][Full Text] [Related]
10. Clinical Overview of MDM2/X-Targeted Therapies.
Burgess A; Chia KM; Haupt S; Thomas D; Haupt Y; Lim E
Front Oncol; 2016; 6():7. PubMed ID: 26858935
[TBL] [Abstract][Full Text] [Related]
11. Targeting USP7-Mediated Deubiquitination of MDM2/MDMX-p53 Pathway for Cancer Therapy: Are We There Yet?
Qi SM; Cheng G; Cheng XD; Xu Z; Xu B; Zhang WD; Qin JJ
Front Cell Dev Biol; 2020; 8():233. PubMed ID: 32300595
[TBL] [Abstract][Full Text] [Related]
12. Functions of MDMX in the modulation of the p53-response.
Lenos K; Jochemsen AG
J Biomed Biotechnol; 2011; 2011():876173. PubMed ID: 21541195
[TBL] [Abstract][Full Text] [Related]
13. High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx.
Czarna A; Popowicz GM; Pecak A; Wolf S; Dubin G; Holak TA
Cell Cycle; 2009 Apr; 8(8):1176-84. PubMed ID: 19305137
[TBL] [Abstract][Full Text] [Related]
14. When the guardian sleeps: Reactivation of the p53 pathway in cancer.
Merkel O; Taylor N; Prutsch N; Staber PB; Moriggl R; Turner SD; Kenner L
Mutat Res Rev Mutat Res; 2017 Jul; 773():1-13. PubMed ID: 28927521
[TBL] [Abstract][Full Text] [Related]
15. Anticancer therapeutic strategies for targeting mutant p53-Y220C.
Chasov V; Davletshin D; Gilyazova E; Mirgayazova R; Kudriaeva A; Khadiullina R; Yuan Y; Bulatov E
J Biomed Res; 2024 May; 38(3):222-232. PubMed ID: 38738269
[TBL] [Abstract][Full Text] [Related]
16. Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells.
Mrkvová Z; Uldrijan S; Pombinho A; Bartůněk P; Slaninová I
Molecules; 2019 Jun; 24(11):. PubMed ID: 31181622
[TBL] [Abstract][Full Text] [Related]
17. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX.
Pazgier M; Liu M; Zou G; Yuan W; Li C; Li C; Li J; Monbo J; Zella D; Tarasov SG; Lu W
Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4665-70. PubMed ID: 19255450
[TBL] [Abstract][Full Text] [Related]
18. Protecting the genome from mdm2 and mdmx.
Melo AN; Eischen CM
Genes Cancer; 2012 Mar; 3(3-4):283-90. PubMed ID: 23150761
[TBL] [Abstract][Full Text] [Related]
19. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
[TBL] [Abstract][Full Text] [Related]
20. Targeting p53-MDM2-MDMX loop for cancer therapy.
Zhang Q; Zeng SX; Lu H
Subcell Biochem; 2014; 85():281-319. PubMed ID: 25201201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
